**Review Article**

**Pulmonary Rehabilitation Can Improve the Functional Capacity and Quality of Life for Pneumoconiosis Patients: A Systematic Review and Meta-Analysis**

Hulei Zhao,1,2 Yang Xie,2,3 Jiajia Wang,2 Xuanlin Li,2 and Jiansheng Li1,2

1Longhua Hospital Shanghai University of Traditional Chinese Medicine, Shanghai, China  
2Co-Construction Collaborative Innovation Center for Chinese Medicine and Respiratory Diseases by Henan & Education Ministry of P.R. China, Zhengzhou, China  
3Department of Respiratory Diseases, The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, China

Correspondence should be addressed to Jiansheng Li; li_js8@163.com

Received 25 January 2020; Revised 10 June 2020; Accepted 7 July 2020; Published 29 July 2020

Academic Editor: Salvatore Battaglia

Copyright © 2020 Hulei Zhao et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

This study evaluated the efficacy and safety of pulmonary rehabilitation (PR) for pneumoconiosis. We systematically searched PubMed, Embase, The Cochrane Library, Web of Science, SinoMed, CNKI, VIP databases and Wanfang Data from their inception to June 1, 2019. A systematic review and meta-analysis of randomized controlled trials (RCTs) of PR for pneumoconiosis was conducted and reported in compliance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). Two reviewers independently screened literature, extracted data, and assessed bias risk. All statistical analyses were performed using the RevMan software. Sixteen RCTs with 1307 subjects were ultimately included for analysis. Compared with routine treatment, PR was able to improve the 6-minute walking distance (mean difference (MD) 69.10, 95% confidence interval (CI) 61.95–76.25); the 36-Item Short Form Health Survey total score (MD 17.60, 95% CI 13.59–21.61); physical function score (MD 15.45, 95% CI 3.20–27.69); role physical score (MD 17.87, 95% CI 12.06–23.69); body pain score (MD 14.34, 95% CI 10.33–18.36); general health score (MD 20.86, 95% CI 16.87–24.84); vitality score (MD 11.66, 95% CI 0.18–23.13); social function score (MD 9.67, 95% CI 1.27–18.08); mental health score (MD 20.60, 95% CI 13.61–27.59); forced vital capacity (FVC) (MD 0.20, 95% CI 0.12–0.29); forced expiratory volume in 1 s (FEV1) (MD 0.23, 95% CI 0.09–0.38); FEV1% (MD 5.19, 95% CI 1.48–8.90); maximal voluntary ventilation (MD 4.47, 95% CI 1.14–7.81); reduction in the St. George’s Respiratory Questionnaire score (MD -9.60, 95% CI -16.40 to -2.80); and the modified Medical Research Council Scale score. Furthermore, PR did not increase the FEV1/FVC (MD 3.61, 95% CI -16.40 to -2.80); nor the emotional score (MD 6.18, 95% CI -23.01 to 35.38) compared with the control. We found no reports of adverse events associated with PR. Thus, to some extent, PR can improve functional capacity and quality of life in patients with pneumoconiosis. However, these results should be interpreted with caution because of high heterogeneity. This trial is registered with registration number CRD42018095266.

1. Introduction

Pneumoconiosis refers to a group of occupational lung diseases characterized by diffuse fibrosis of the lung tissue. It is caused mainly by long-term inhalation and deposition of mineral dust, with varying levels of pathogenicity, into the lungs during occupational activities [1–6]. There are 12 forms of occupational pneumoconiosis prescribed by the law in China, of which silicosis and coal worker pneumoconiosis are the most common. Patients with pneumoconiosis are typically affected by cough, expectoration, chest distress, and dyspnea [1]. Pneumoconiosis is a progressive and irreversible but preventable lung disease [7, 8]. It compromises personal health and can cause serious harm among families [9, 10].

According to the statistical bulletin on the development of health and health services in China in 2018, 19 468 cases of occupational pneumoconiosis were reported, accounting...
for 82.85% of a total of 23,497 cases of occupational diseases [11]. The prevalence of silicosis from 2002 to 2016 was 12.7% [12]. The number of new cases of pneumoconiosis in China showed an upward trend from 2000 to 2016 and a slight decline after 2016 [13, 14]. At present, more than 87,000 cases of pneumoconiosis have been reported in China [15], with a mortality as high as 31.2% [16]. Particularly, long-term exposure to silica dust is associated with substantially increased mortality [17]. However, various reports indicate that the actual number of patients with pneumoconiosis in China has exceeded 6 million [18].

No specific drugs or other treatment methods currently exist for pneumoconiosis [19]. Therefore, the management of the condition should first strengthen a comprehensive approach to overall health and active interventions (including symptomatic treatment, complication/combination treatment, and rehabilitative treatment) to reduce pain, delay progression of the disease, and prolong the life of the patient [1]. Comprehensive intervention has been clearly demonstrated to alleviate dyspnea and improve exercise performance and the health-related quality of life (QoL) [20]. Comprehensive interventions, including exercise training, education and behavioral change, and pulmonary rehabilitation (PR), have been widely used in the treatment of respiratory diseases and can effectively yield sustained improvement in functional capacity and reduced need for clinical care [21–26].

Exercise training can improve physical ability and the quality of life in patients with nonmalignant respiratory diseases. However, generally, fewer patients with pneumoconiosis have been included in previous relevant studies [27]. Recently, several randomized controlled trials (RCTs) of PR in the treatment of pneumoconiosis have also been reported. To further evaluate the efficacy and safety of PR for pneumoconiosis, we included a comparatively greater number of patients with pneumoconiosis and conducted a meta-analysis.

2. Materials and Methods

This systematic review and meta-analysis was conducted in accordance with the Cochrane Handbook for Systematic Reviews of Interventions [28], and reported in compliance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) [29] (Supplementary data: Table S1). The study protocol was prospectively registered in the International Prospective Register of Systematic Reviews (PROSPERO) registry (CRD42018095266) and published [30].

2.1. Eligibility Criteria

2.1.1. Study Type and Participants. All published RCTs with a parallel, cluster, or crossover design of PR for patients with pneumoconiosis were included. Only studies in which the authors specifically noted a diagnosis of pneumoconiosis were considered for inclusion.

2.1.2. Intervention. The intervention on which we were focused was PR, based on exercise training. Furthermore, the intervention may or may not have included health education, nutritional intervention, and/or psychosocial support.

2.1.3. Outcomes

(1) Primary Outcomes. The primary outcome measures were functional capacity and health-related QoL, as measured by the 6-minute walking distance (6MWD) and St. George’s Respiratory Questionnaire (SGRQ).
(2) Secondary Outcomes. The secondary outcome measures were pulmonary function, modified Medical Research Council (mMRC) dyspnea scale, 36-Item Short Form Health Survey (SF-36), acute exacerbations, and adverse events.

2.2. Search Strategy. We conducted a systematic search of PubMed, Embase, The Cochrane Library, Web of Science, SinoMed, CNKI, VIP databases and Wanfang Data from their inception to June 1, 2019, using search terms comprising medical subject headings (MeSH) and free-text terms. We developed detailed search strategies for each electronic database, without language restrictions, to attempt to identify all eligible studies. The search strategy for PubMed is shown in Table 1. The search terms were modified and adapted in other databases. We also conducted a search on the websites of ClinicalTrials.gov, the WHO International Clinical Trials Registry platform, Chinese Clinical Trial Registry, and Conference Proceedings Index (Web of Science Core Collection) to identify additional ongoing or unpublished studies. References of the retrieved articles and previous reviews were also checked manually to identify additional potentially eligible studies.

2.3. Trial Selection. After records were imported into the EndNote reference management software (Clarivate Analytics), duplicate records were removed. Two reviewers (J-JW and X-LL) independently examined titles and abstracts and selected all potentially eligible studies. Full-text articles were then obtained and reviewed independently, based on the inclusion criteria. We resolved all disagreements by consensus, and a third reviewer (H-LZ) acted as an arbiter when consensus could not have been achieved. Details of the selection process are presented in Figure 1.

2.4. Data Extraction. Two investigators (J-JW and X-LL) independently extracted data from the included studies. Disagreements were solved by consultation with the third reviewer (H-LZ). Structured and standardized data extraction sheets were completed for every study included in the review. Those sheets included details of the authors, year of publication, study design, characteristics of participants, intervention, comparator, and outcomes.

2.5. Risk-of-Bias Assessment. Methodological quality was independently assessed using the Cochrane Collaboration's

**Figure 1: Selection of RCTs for the meta-analysis.**
tool for assessing the risk of bias [31–33]. The assessment details included sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessors, incomplete outcome data, selective reporting, and other sources of bias. Each domain was assessed as "low risk," "high risk," or "unclear risk," according to the description details of the eligible studies. We summarized the risk of bias and solved differences in author interpretation of the data through discussion.

2.6. Quality of Evidence Assessment. We also evaluated the quality of evidence for the outcome measures using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system [34]. The GRADE system divides the quality of evidence into four levels: high, medium, low, and very low. A summary table was prepared using the GRADE profiler (GRADEpro, version 3.6).

2.7. Data Analysis. For continuous data, we calculated the mean differences (MD) with 95% confidence intervals (CI). When different units of measurement were employed, each unit was converted to the most common. For example, we converted the “month” or “year” into “weeks.”

The \( \chi^2 \) test for heterogeneity was performed. We used the random effects model across all analyses, to address clinical heterogeneity of the included population, as well as variations in treatment duration. Publication bias was assessed via a funnel plot.

We also performed subgroup analyses according to different intervention forms (exercise training and health education or exercise training and health education combined with other measures) and durations of PR (<3 months or ≥3 months). We excluded studies in succession and compared the results through sensitivity analysis. All statistical analyses were performed using the Review Manager (RevMan) software [35]. Publication bias was assessed by Begg’s test and Egger’s test with the STATA software version 12.0 [36].

3. Results

3.1. Results of the Search. A total of 2481 studies were retrieved following both electronic and manual searches.

| Study | Country | Study type | No. of patients PR | Interventions PR | Control | Course of treatment |
|-------|---------|------------|--------------------|-----------------|---------|--------------------|
| Yun X 2015 [37] | China | RCT | 50 | Exercise training+health education | Routine treatment | 12 month |
| Zhang ZH 2012 [38] | China | RCT | 80 | Exercise training+health education+respiratory training | Routine treatment | 2 month |
| Wang F 2017 [39] | China | RCT | 26 | Exercise training+health education | Routine treatment | 2 month |
| Qu WJ 2017 [40] | China | RCT | 41 | Exercise training+health education | Routine treatment | 3 month |
| Pan W 2017 [41] | China | RCT | 30 | Exercise training+health education+respiratory training | Routine treatment | 2 month |
| Liu QG 2009 [42] | China | RCT | 35 | Exercise training+health education+nutritional guidance+psychological counseling | Routine treatment | 3 month |
| Liu J 2015 [43] | China | RCT | 41 | Exercise training+health education | Routine treatment | 3 month |
| Li XY 2014 [44] | China | RCT | 100 | Exercise training+health education | Routine treatment | 2 month |
| Li F 2015 [45] | China | RCT | 40 | Exercise training+health education+respiratory training+psychological counseling+nutritional guidance | Routine treatment | 6 month |
| Jin YK 2014 [46] | China | RCT | 52 | Exercise training+health education+respiratory training+psychological counseling | Routine treatment | 6 month |
| Cao DF 2010 [47] | China | RCT | 30 | Exercise training+health education+respiratory training | Routine treatment | 2 month |
| Dale 2014 [48] | Australia | RCT | 6 | Exercise training | Routine treatment | 4 month |
| Ma LL 2014 [49] | China | RCT | 30 | Exercise training+respiratory training+psychological counseling+nutritional guidance | Routine treatment | 1.5 month |
| Liu CZ 2014 [50] | China | RCT | 30 | Exercise training+health education+respiratory training | Routine treatment | 6 month |
| Dong QA 2009 [51] | China | RCT | 32 | Exercise training+health education+respiratory training | Routine treatment | 3 month |
| Xiao SY 2019 [52] | China | RCT | 32 | Exercise training+health education+respiratory training | Routine treatment | 6 month |
After the removal of the duplicates and screening of the titles and abstracts, 40 articles were deemed potentially eligible. After reviewing the full-text articles, 16 trials [37–52] were included in the final analysis. The screening process is summarized in a flow diagram (Figure 1).

3.2. Characteristics of the Included Studies. This review included 16 RCTs published from 2009 to 2019, with a minimum sample size of 10 and a maximum of 200. The total numbers of patients in the PR group and control group were 655 and 652, respectively. The duration of treatment ranged from 1.5 to 12 months. The characteristics of the included studies are presented in Table 2.

3.3. Assessment of Risk of Bias. Of the 16 included studies, 14 were judged to show unclear risk and 2, high risk. Four studies described randomization methods, of which two used a random table of numbers, one used a lottery, and one used a computer-generated randomization program. One study used allocation concealment via a lottery. Participants were not blinded to the specific intervention in any of the studies. In one study, the assessor was blinded. Three studies reported loss to follow-up and dropouts. Two studies did not report the primary outcomes. The results of risk of bias assessment are summarized in Figures 2 and 3. The statements for risk of bias for all 16 included studies are shown in Table 3.

3.4. Primary Outcomes

3.4.1. 6MWD. Twelve studies were included in the meta-analysis. The between-study heterogeneity was low for the 6MWD (MD 69.10, 95% CI 61.95 to 76.25, \( P < 0.001, I^2 = 4\%\)) compared with the control (Figure 4).

3.4.2. SGRQ. Four studies were included in the meta-analysis. The between-study heterogeneity was high for the SGRQ. The results showed that PR could reduce the SGRQ score (MD -9.60, 95% CI -16.40 to -2.80, \( P = 0.006, I^2 = 88\%\)) compared with the control (Figure 5).

3.5. Secondary Outcomes

3.5.1. Forced Vital Capacity (FVC). Three studies were included in the meta-analysis. The between-study heterogeneity was low for FVC. The results showed that PR could increase the FVC (MD 0.20, 95% CI 0.12 to 0.29, \( P < 0.001, I^2 = 14\%\)) compared with the control (Figure 6).

3.5.2. Forced Expiratory Volume in 1 s (FEV1). Five studies were included in the meta-analysis. The between-study heterogeneity was high for the FEV1. The results showed that PR could significantly increase the FEV1 (MD 0.23, 95% CI 0.09 to 0.38, \( P = 0.002, I^2 = 77\%\)) compared with the control (Figure 7).

3.5.3. FEV1%. Six studies were included in the meta-analysis. The between-study heterogeneity was high for the FEV1%. The results showed that PR could significantly increase the FEV1% (MD 5.19, 95% CI 1.48 to 8.90, \( P = 0.006, I^2 = 93\%\)) compared with the control (Figure 8).

3.5.4. FEV1/FVC. Seven studies were included in the meta-analysis. The between-study heterogeneity was high for the FEV1/FVC. The results showed that PR was not able to increase the FEV1/FVC (MD 3.61, 95% CI -3.43 to 10.65, \( P = 0.32, I^2 = 99\%\)) compared with the control (Figure 9).

3.5.5. Maximal Voluntary Ventilation (MVV). Four studies were included in the meta-analysis. The between-study heterogeneity was high for the MVV. The results showed that PR could significantly increase the MVV (MD 4.47, 95% CI 1.14 to 7.81, \( P = 0.009, I^2 = 77\%\)) compared with the control (Figure 10).
3.5.6. mMRC. One study was included in the meta-analysis. The results showed that PR could reduce the mMRC compared with the control (Figure 11).

3.5.7. SF-36. Two studies were included in the meta-analysis. The between-study heterogeneity was high for the SF-36 total score and the physical function (PF), vitality (VT), social function (SF), mental health (MH), and emotional (RE) scores. Furthermore, the between-study heterogeneity was low for the role physical (RP), body pain (BP), and general health (GH) scores. The results showed that PR could increase the SF-36 total score (MD 17.60, 95% CI 13.59 to 21.61, \( P < 0.001 \), \( I^2 = 54\% \)); PF score (MD 15.45, 95% CI 9.67 to 21.61, \( P < 0.001 \), \( I^2 = 85\% \)); RP score (MD 17.87, 95% CI 12.06 to 23.69, \( P < 0.001 \), \( I^2 = 0\% \)); BP score (MD 14.34, 95% CI 10.33 to 18.36, \( P < 0.001 \), \( I^2 = 0\% \)); GH score (MD 20.86, 95% CI 16.87 to 24.84, \( P < 0.001 \), \( I^2 = 0\% \)); VT score (MD 11.66, 95% CI 0.18 to 23.13, \( P = 0.05 \), \( I^2 = 91\% \)); SF score (MD 9.67, 95% CI 1.27 to 18.08, \( P = 0.02 \), \( I^2 = 78\% \)); and MH score (MD 20.60, 95% CI 13.61 to 27.59, \( P < 0.001 \), \( I^2 = 73\% \)) compared with the control. However, PR was not able to increase the RE score (MD 6.18, 95% CI -23.01 to 35.38, \( P = 0.68 \), \( I^2 = 94\% \)) compared with the control (Figure 12).

3.6. Subgroup Analysis. We conducted subgroup analysis of the intervention and duration of PR. No statistical differences were noted in the improvement of the 6MWD among different subgroups. However, statistical differences were noted in the improvement of FEV1% between exercise training plus health education and exercise training plus health education combined with other measures. Compared with exercise training plus health education, exercise training plus health education combined with other measures showed more favorable results in improving SGRQ scores and MVV (Table 4). Results of all subgroup analyses in the meta-analysis are presented in the Supplementary materials: Figure S1-S13.

3.7. Sensitivity Analysis. To further confirm the robustness of the results, we conducted a sensitivity analysis. We excluded studies one at a time and compared the results of the analysis. We found no considerable change in the direction of the overall effects of the SGRQ score, FEV1, FEV1%, FEV1/FVC, or MVV. However, we noted a change in the direction of the overall effects of FVC when two studies were excluded (Pan et al., 2017; Yun et al., 2015) (Table 5).

3.8. Quality of Evidence. The overall quality of evidence, according to the primary outcome measures, was moderate or low. The GRADE evidence profiles of the primary outcomes are shown in Table 6.

3.9. Publication Bias. A funnel plot was used to evaluate publication bias. We found no potential publication bias among the included trials (Figure 13) (Begg’s test \( P = 0.15 \) and Egger’s test \( P = 0.33 \)).

3.10. Limitations. We had hoped to also evaluate the effects of PR on acute exacerbations of pneumoconiosis and the occurrence of adverse events in patients with PR. However, the 16 studies included did not report acute exacerbations or adverse events. Therefore, the present analysis could not report them. This is a major limitation of this systematic review.

4. Discussion

Sixteen RCTs with 1307 subjects were ultimately included in the analysis. The main findings of the present study indicated that PR can be effective in patients with pneumoconiosis, as evidenced by the changes in the 6MWD, SGRQ, mMRC, SF-36, and pulmonary function. No adverse events were reported in any of the included studies.
| Study                  | Random sequence generation (selection bias) | Allocation concealment (selection bias) | Blinding of participants and personnel (performance bias) | Blinding of outcome assessment (detection bias) | Incomplete outcome data (attrition bias) | Selective reporting (reporting bias) | Other bias |
|-----------------------|---------------------------------------------|----------------------------------------|------------------------------------------------------------|-----------------------------------------------|----------------------------------------|------------------------------------|------------|
| Yun X 2015 [37]        | Uncertain risk                              | Uncertain risk                         | No                                                         | Uncertain risk                               | Complete                               | Uncertain risk                     | Uncertain risk |
| Zhang ZH 2012 [38]     | Uncertain risk                              | Uncertain risk                         | No                                                         | Uncertain risk                               | Uncertain risk                         | Uncertain risk                     | Uncertain risk |
| Wang F 2017 [39]       | Uncertain risk                              | Uncertain risk                         | No                                                         | Uncertain risk                               | Uncertain risk                         | Uncertain risk                     | Uncertain risk |
| Qu WJ 2017 [40]        | Uncertain risk                              | Uncertain risk                         | No                                                         | Uncertain risk                               | Uncertain risk                         | Uncertain risk                     | Uncertain risk |
| Pan W 2017 [41]        | Uncertain risk                              | Uncertain risk                         | No                                                         | Uncertain risk                               | Uncertain risk                         | Uncertain risk                     | Uncertain risk |
| Liu QG 2009 [42]       | Uncertain risk                              | Uncertain risk                         | No                                                         | Uncertain risk                               | Uncertain risk                         | Uncertain risk                     | Uncertain risk |
| Liu J 2015 [43]        | Random number table                         | Uncertain risk                         | No                                                         | Uncertain risk                               | Uncertain risk                         | Uncertain risk                     | Uncertain risk |
| Li XY 2014 [44]        | Uncertain risk                              | Uncertain risk                         | No                                                         | Uncertain risk                               | Uncertain risk                         | Uncertain risk                     | Uncertain risk |
| Li F 2015 [45]         | Uncertain risk                              | Uncertain risk                         | No                                                         | Uncertain risk                               | Uncertain risk                         | Uncertain risk                     | Uncertain risk |
| Jin YK 2014 [46]       | Uncertain risk                              | Uncertain risk                         | No                                                         | Uncertain risk                               | Uncertain risk                         | Uncertain risk                     | Uncertain risk |
| Cao DF 2010 [47]       | Uncertain risk                              | Uncertain risk                         | No                                                         | Uncertain risk                               | Uncertain risk                         | Uncertain risk                     | Uncertain risk |
| Dale 2014 [48]         | Computer-generated randomization program    | Uncertain risk                         | No                                                         | Assessor blind                               | Complete                               | No                                 | No          |
| Ma LL 2014 [49]        | Uncertain risk                              | Uncertain risk                         | No                                                         | Uncertain risk                               | Without the primary outcomes           | Uncertain risk                     | Uncertain risk |
| Liu CZ 2014 [50]       | Lottery                                     | Lottery                                 | No                                                         | Uncertain risk                               | Uncertain risk                         | Uncertain risk                     | Uncertain risk |
| Dong QA 2009 [51]      | Uncertain risk                              | Uncertain risk                         | No                                                         | Uncertain risk                               | Without the primary outcomes           | Uncertain risk                     | Uncertain risk |
| Xiao SY 2019 [52]      | Random number table                         | Uncertain risk                         | No                                                         | Uncertain risk                               | Complete                               | No                                 | No          |
The mean improvement in the 6MWD following PR was 69.10 m, which exceeds the mean improvement of 44.34 m observed in people with COPD who have undergone PR [23] and the minimal clinically important difference (24–45 m) for idiopathic pulmonary fibrosis [53]. In the present study, we also found that PR could reduce the SGRQ score compared with the control. The mean reduction in the SGRQ score following PR was 9.60, which exceeds the minimal clinically important difference for COPD [54, 55].

We also found that PR reduced the mMRC score and increased the SF-36 score, compared with the control. Regarding pulmonary function, PR was able to improve the

---

**Table 1: Summary of Studies and Results**

| Study or subgroup | Pulmonary rehabilitation Mean | Pulmonary rehabilitation SD | Pulmonary rehabilitation Total | Routine treatment Mean | Routine treatment SD | Routine treatment Total | Mean difference IV, random, 95% CI | Mean difference IV, random, 95% CI |
|------------------|-------------------------------|----------------------------|--------------------------------|------------------------|----------------------|------------------------|-----------------------------------|-----------------------------------|
| Cao DF 2010      | 100.25                        | 133.65                     | 30                             | -0.88                  | 107.09               | 32                     | 1.4%                              | 101.13 [40.60, 161.66]             |
| Dale 2014        | 39.5                          | 29.21                      | 6                              | -1.9                   | 44.38                | 4                      | 2.1%                              | 58.50 [9.13, 107.87]              |
| Jin YK 2014      | 98.16                         | 137.16                     | 52                             | 58.26                  | 114.74               | 50                     | 2.1%                              | 39.90 [9.10, 88.90]              |
| Li F 2015        | 74                            | 57.86                      | 40                             | 6                     | 51.73                | 40                     | 8.5%                              | 68.00 [43.95, 92.05]              |
| Li XY 2014       | 91.7                          | 81.74                      | 100                            | 12.2                   | 60.32                | 100                    | 12.1%                             | 79.50 [59.59, 99.41]              |
| Liu J 2015       | 70.41                         | 47                          | 41                              | 7                     | 42.8                 | 41                     | 12.6%                             | 63.41 [43.95, 82.87]              |
| Liu QG 2009      | 153                           | 34.04                      | 35                              | 70                    | 34.6                 | 25                     | 15.2%                             | 83.00 [65.36, 100.64]             |
| Pan W 2017       | 87.28                         | 46.3                       | 30                              | 11.38                  | 42.91                | 30                     | 9.5%                              | 75.90 [53.31, 98.49]              |
| Qu WJ 2017       | 71.11                         | 51.35                      | 41                              | 7.01                   | 42.81                | 41                     | 11.5%                             | 64.10 [43.64, 84.56]              |
| Wang F 2017      | 31.06                         | 81.22                      | 26                              | 1.91                   | 75.04                | 25                     | 2.7%                              | 29.15 [-13.74, 72.04]             |
| Yun X 2015       | 57.15                         | 66.17                      | 50                              | 3.66                   | 77.93                | 50                     | 6.2%                              | 53.49 [25.15, 81.83]              |
| Zhang ZH 2012    | 74                            | 57.86                      | 80                              | 6                     | 51.73                | 80                     | 16.2%                             | 68.00 [50.99, 85.01]              |

Total (95% CI) 531  518  100.0%  69.10 [61.95, 76.25]

Heterogeneity: τ² = 6.76; ch² = 11.48, df = 11 (P = 0.40); I² = 4%

Test for overall effect: Z = 18.95 (P < 0.000001)

---

**Figure 4: Forest plot showing the effect of PR on the 6MWD for pneumoconiosis.**

**Figure 5: Forest plot showing the effect of PR on the SGRQ score for pneumoconiosis.**

**Figure 6: Forest plot showing the effect of PR on the FVC for pneumoconiosis.**

**Figure 7: Forest plot showing the effect of PR on the FEV1 for pneumoconiosis.**
FVC, FEV1, FEV1%, and MVV in patients with pneumoconiosis. However, these improvements were likely too small to show clinical significance and cannot induce any considerable improvement in the FEV1/FVC. These findings suggest that patients with pneumoconiosis can benefit from PR, as it can improve exercise ability and the quality of life. The results of subgroup analysis showed that prolonging the duration of PR or combining exercise training with other forms of rehabilitation, such as nutritional intervention and psychosocial support, may improve SGRQ scores and pulmonary function.

At present, pneumoconiosis is still considered an incurable and irreversible disease, and the quality of life among patients with pneumoconiosis is low [56, 57]. As the treatment goal for pneumoconiosis is to alleviate symptoms or prevent deterioration, we propose that the current guidelines should include PR as a routine treatment for pneumoconiosis. We found that PR in patients with pneumoconiosis was
generally safe and well tolerated. Thus, the present evidence, at least to some extent, supports the fact that PR can be recommended for patients with pneumoconiosis.

Specific weaknesses and shortcomings of the present study must be acknowledged, which may reduce the credibility of the results. First, almost all trials were conducted in...
| Intervention subgroup                  | 6MWD (MD, 95% CI)   | SGRQ (MD, 95% CI) | FVC (MD, 95% CI) | FVV1 (MD, 95% CI) | FEV1% (MD, 95% CI) | FEV1/FVC (MD, 95% CI) | MVV (MD, 95% CI) |
|---------------------------------------|---------------------|-------------------|------------------|-------------------|-------------------|----------------------|-----------------|
| All studies                           | 69.10 [-61.95, 76.25] | -9.60 [-16.40, -2.80] | 0.20 [0.12, 0.29] | 0.23 [0.09, 0.38] | 5.19 [1.48, 8.90] | 3.61 [-3.43, 10.65] | 4.47 [1.14, 7.81] |
| Time subgroup                         |                     |                   |                  |                   |                   |                      |                 |
| ≥3 months                             | 67.43 [58.32, 76.54] | -16.84 [-21.45, -12.23] | 0.26 [0.03, 0.49] | 0.27 [0.13, 0.41] | 5.73 [1.80, 9.66] | /                    | 8.21 [5.07, 11.34] |
| <3 months                             | 71.30 [57.68, 84.92] | -3.64 [-6.20, -1.09] | 0.16 [-0.01, 0.33] | 0.15 [-0.28, 0.58] | 3.98 [-1.43, 9.39] | /                    | 2.28 [1.25, 3.32] |

*P < 0.05 for subgroup differences.
China, which may limit generalizability. Second, some weaknesses in methodology may have had considerable effects on the results. For example, only four trials clearly reported the randomization methods used. Only three trials reported the randomization methods used. Only three trials reported attrition. Only one clinical trial was formally registered. Furthermore, we only evaluated effects after rehabilitation and found that patients may have derived more benefits by prolonging the duration of PR. However, we were unable to determine the best course of PR or evaluate the long-term effects of PR. Similar to the problems encountered in most systematic reviews, our analyses were greatly affected by heterogeneity. This is a major issue, on which we need to focus in the next steps of our research.

There are currently no effective drugs or measures to treat fibrosis due to pneumoconiosis. Our findings have important implications worldwide, for both policymakers and clinicians. We should apply PR as a routine treatment for pneumoconiosis.

5. Conclusions

Our results show that PR can improve patients’ quality of life and functional capacity. However, the quality of the research included in the present study was low, which limits the strength of the inferences that can be drawn. This issue needs further investigation through a well-designed RCT. There is also a need for follow-up data, to demonstrate the extent to
which the effects of PR are maintained over time. Future studies should also pay attention to the specific types of patients with pneumoconiosis who can derive the most benefit from PR. We should also try to determine which form of PR is the most effective and the best course of treatment. Multicenter RCTs of PR for pneumoconiosis are needed worldwide, in order to generalize the results.

Long-term exposure to mineral dust can severely compromise clearance and defense mechanisms of the respiratory system. A chronic, progressive course of disease can lead to reduced patient immunity, which can eventually lead to a variety of complications. Complications can have considerable impact on the treatment, progression, and prognosis of pneumoconiosis and can be a direct cause of patient deaths. Timely diagnosis and treatment of various complications are crucial to improving the condition of the patients, prolonging their lives, and improving their quality of life. Therefore, in our future research, we would focus on the efficacy of PR for patients with comorbidities.

The results of this study, at least to an extent, support the use of PR to improve respiratory function and the quality of life in patients with pneumoconiosis; however, we should treat the results cautiously because of the high heterogeneity among studies in the present analysis.

**Disclosure**

The funders had no role in the study design, data collection and analysis, or interpretation of the data.

**Conflicts of Interest**

All authors declare that they have no conflict of interest regarding the publication of this paper.

**Authors’ Contributions**

J.L. and H.Z. conceived and designed the study; J.W. and X.L. collected the data; H.Z., J.W., and X.L. analyzed the data; Y.X., J.L., and H.Z. wrote the paper; all coauthors participated in revising the manuscript and approved the version submitted for publication.

**Acknowledgments**

This work was supported by Henan Province Priority and Advantage Discipline Construction Engineering Projects-Traditional Chinese Medicine (No. STS-ZYX-2017025); Program for Science and Technology Innovation Talents in Universities of Henan Province (No. 19HASTIT008); National Public Welfare Industry Research Project-Traditional Chinese Medicine Industry (No. 201507001-01); Special Subject of Chinese Medicine Research of Henan Province (No. 2018ZY1003); and Key Scientific Research
Projects of Colleges and Universities in Henan Province (No. 19A360026).

Supplementary Materials

Supplementary 1. Table S1: PRISMA checklist.

Supplementary 2. Figure S1: subgroup analysis of intervention for 6MWD.

Supplementary 3. Figure S2: subgroup analysis of intervention for SGRQ.

Supplementary 4. Figure S3: subgroup analysis of intervention for FVC.

Supplementary 5. Figure S4: subgroup analysis of intervention for FEV1.

Supplementary 6. Figure S5: subgroup analysis of intervention for FEV1%.

Supplementary 7. Figure S6: subgroup analysis of intervention for FVC.

Supplementary 8. Figure S7: subgroup analysis of intervention for MVV.

Supplementary 9. Figure S8: subgroup analysis of duration for 6MWD.

Supplementary 10. Figure S9: subgroup analysis of duration for SGRQ.

Supplementary 11. Figure S10: Subgroup analysis of duration for FVC.

Supplementary 12. Figure S11: subgroup analysis of duration for FEV1.

Supplementary 13. Figure S12: subgroup analysis of duration for FEV1%.

Supplementary 14. Figure S13: subgroup analysis of duration for MVV.

References

[1] Occupational Lung Disease Group of Labor Hygiene and Occupational Diseases Branch of Chinese Preventive Medicine Association, “Consensus of Chinese experts on pneumoconiosis treatment(2018),” Journal of Environmental and Occupational Medicine, vol. 35, no. 8, pp. 677–689, 2018.

[2] P. Cullinan and P. Reid, “Pneumoconiosis,” Primary Care Respiratory Journal, vol. 22, no. 2, pp. 249–252, 2013.

[3] National Health and Family Planning Commission of the People’s Republic of China, GBZ 70-2015 National occupational health standards, China Quality and Standards Publishing & Media Co., Ltd., 2018.

[4] M. Mlika and R. Adigun, “Silicosis (Coal Worker Pneumoconiosis),” in StatPearls, StatPearls Publishing StatPearls Publishing LLC, Treasure Island (FL), 2018.

[5] V. Castranova and V. Valiyathan, “Silicosis and coal workers’ pneumoconiosis,” Environmental Health Perspectives, vol. 108, Supplement 4, pp. 675–684, 2000.

[6] C. C. Leung, I. T. S. Yu, and W. Chen, “Silicosis,” The Lancet, vol. 379, no. 9830, pp. 2008–2018, 2012.

[7] G. R. Zosky, R. F. Hoy, E. J. Silverstone et al., “Coal workers’ pneumoconiosis: an Australian perspective,” The Medical Journal of Australia, vol. 204, no. 11, pp. 414–418, 2016.

[8] C. M. Yen, C. L. Lin, M. C. Lin, H. Y. Chen, N. H. Lu, and C. H. Kao, “Pneumoconiosis increases the risk of congestive heart failure: a nationwide population-based cohort study,” Medicine (Baltimore), vol. 95, no. 25, article e3972, 2016.

[9] F. Shen, H. Liu, J. Yuan et al., “Cost-effectiveness of coal workers’ pneumoconiosis prevention based on its predicted incidence within the Datong Coal Mine Group in China,” PLoS One, vol. 10, no. 6, article e0130958, 2015.

[10] H. Liu, B. Yan, B. Han, J. Sun, Y. Yang, and J. Chen, “Assessment of respiration-related quality of life of Chinese patients with silicosis and its influencing factors using the St. George’s Respiratory Questionnaire (SGRQ),” Journal of Clinical Nursing, vol. 21, no. 11-12, pp. 1515–1523, 2012.

[11] National Health Commission of the People’s Republic of China, Statistical Bulletin on the Development of Health Care in China in 2018, http://www.nhc.gov.cn/guiduixxs/s10748/201905/9b88d52727cf346049de8acce25fcbd0.shtml.

[12] Q. Yang, H. Wang, L. Liu, X. Zhang, and X. Zou, “Prevalence of silicosis among workers exposed to silica dust in China during 2002–2016: a meta-analysis,” Zhong Guo Gong Ye Yi Xue Za Zhi, vol. 31, no. 4, pp. 307–308, 2018.

[13] Y. Li, X. L. Tang, and X. B. Xiao, “New research progress of pneumoconiosis therapy,” Occupation and Health, vol. 29, no. 19, pp. 2561–2563, 2013.

[14] M. Zhang, D. Wang, Y. D. Zheng, X. Y. Du, and S. Y. Chen, “Analyses on the characteristics and the trends of pneumoconiosis notified between 1997 and 2009, in China,” Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi, vol. 31, no. 5, pp. 321–334, 2013.

[15] X. J. Zhu, P. Xiao, D. Wang et al., “Analysis on disease burden of pneumoconiosis in Chinese population from 1990 to 2017,” Chinese Journal of Industrial Medicine, vol. 32, no. 5, pp. 341–346, 2019.

[16] H. Tang, Y. Wang, H. Chen, J. Xu, and B. Li, “Case fatality rate in patients with pneumoconiosis in China: a meta-analysis,” Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi, vol. 33, no. 3, pp. 229–232, 2015.

[17] W. Chen, Y. Liu, H. Wang et al., “Long-term exposure to silica dust and risk of total and cause-specific mortality in Chinese workers: a cohort study,” PLoS Medicine, vol. 9, no. 4, article e1001206, 2012.

[18] L. Liu, “China’s dusty lung crisis: rural-urban health inequity as social and spatial injustice,” Social Science & Medicine, vol. 233, pp. 218–228, 2019.

[19] Y. X. Liang, O. Wong, H. Fu, T. X. Hu, and S. Z. Xue, “The economic burden of pneumoconiosis in China,” Occupational and Environmental Medicine, vol. 60, no. 6, pp. 383–384, 2003.

[20] L. Nici, C. Donner, E. Wouters et al., “American Thoracic Society/European Respiratory Society statement on pulmonary rehabilitation,” American Journal of Respiratory and Critical Care Medicine, vol. 173, no. 12, pp. 1390–1413, 2006.

[21] U. Ochmann, N. Kotschy-Lang, W. Raab, J. Kellberger, D. Nowak, and R. A. Jörres, “Long-term efficacy of pulmonary rehabilitation in patients with occupational respiratory diseases,” Respiration, vol. 84, no. 5, pp. 396–405, 2012.
[22] E. W. Tsang, H. Kwok, A. K. Y. Chan et al., “Outcomes of community-based and home-based pulmonary rehabilitation for pneumoconiosis patients: a retrospective study,” *BMC Pulmonary Medicine*, vol. 18, no. 1, p. 133, 2018.

[23] L. Dowman, C. J. Hill, and A. E. Holland, “Pulmonary rehabilitation for interstitial lung disease,” *Cochrane Database of Systematic Reviews*, no. 10, article CD006322, 2014.

[24] A. R. Jenkins, H. Gowler, F. Curtis, N. S. Holden, C. Bridle, and C. K. Ryrsø, N. S. Godtfredsen, L. M. Kofod et al., “L. Nici and R. L. ZuWallack,” *Review Manager (RevMan)* [Computer program]. Version 5.0, Nordic Cochrane Centre, Cochrane Collaboration, 2008.

[25] M. Huang, J. Zhao, Y. Huang, L. Dai, and X. Zhang, “Meta-analysis of urinary C-terminal telopeptide of type II collagen as a biomarker in osteoarthritis diagnosis,” *Journal of Orthopaedic Translation*, vol. 13, pp. 50–57, 2018.

[26] X. Yun, “Therapeutic effect of rehabilitation therapy based on one year movement in patients with coal worker’s pneumoconiosis in Datong Coal Mine Group,” North China University of Science and Technology, 2015.

[27] J. P. T. Higgins and S. Green, *Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0*, The Cochrane Collaboration, 2011.

[28] D. Moher, A. Liberati, J. Tetzlaff, D. G. Altman, and for the PRISMA Group, “Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement,” *BMJ*, vol. 339, article b2535, 2009.

[29] H. Zhao, Y. Xie, J. Wang, X. Li, and J. Li, “Pulmonary rehabilitation for pneumoconiosis: protocol for a systematic review and meta-analysis,” *BMJ Open*, vol. 9, no. 8, article e025891, 2019.

[30] J. P. T. Higgins and S. Green, *Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0*, Wiley-Blackwell, 2011.

[31] S. S. Wu, F. Sun, and S. Y. Zhan, “Bias risk assessment: (3) revised Cochrane bias risk assessment tool for individual randomized, cross-over trials (RoB2.0),” *Zhonghua Liu Xing Bing Xue Za Zhi*, vol. 38, no. 10, pp. 1436–1440, 2017.

[32] X. Z. Lu, F. Sun, and S. Y. Zhan, “Risk related to bias assessment: (4) revised Cochrane Risk of Bias Tool for cluster-randomized control trials (RoB2.0),” *Zhonghua Liu Xing Bing Xue Za Zhi*, vol. 39, no. 2, pp. 240–244, 2018.

[33] G. H. Guyatt, A. D. Oxman, G. E. Vist et al., “GRADE: an emerging consensus on rating quality of evidence and strength of recommendations,” *BMJ*, vol. 336, no. 7650, pp. 924–926, 2008.

[34] M. Clarke and A. Oxman, *Review Manager (RevMan) [Computer program]. Version 5.0*, Nordic Cochrane Centre, Cochrane Collaboration, 2008.

[35] M. Huang, J. Zhao, Y. Huang, L. Dai, and X. Zhang, “Meta-analysis of urinary C-terminal telopeptide of type II collagen as a biomarker in osteoarthritis diagnosis,” *Journal of Orthopaedic Translation*, vol. 13, pp. 50–57, 2018.

[36] X. Yun, “Therapeutic effect of rehabilitation therapy based on one year movement in patients with coal worker’s pneumoconiosis in Datong Coal Mine Group,” North China University of Science and Technology, 2015.

[37] Z. H. Zhang, B. Shang, X. Y. Li, and W. J. Zhang, “Observation on the curative effect of pulmonary rehabilitation therapy in patients with pneumoconiosis,” *Chinese Journal of Industrial Hygiene and Occupational Diseases*, vol. 30, no. 8, pp. 612–613, 2012.

[38] F. Wang, “Effect of comprehensive treatment on exercise endurance of patients with coal worker’s pneumoconiosis,” *For all Health*, vol. 5, no. 11, 2017.

[39] J. P. T. Higgins and S. Green, “Application of health education and exercise training in improving pulmonary function of pneumoconiosis patients,” *Chinese Journal of Convalescent Medicine*, vol. 26, no. 3, pp. 331–334, 2017.

[40] W. Pan and J. L. Chen, “Effect of rehabilitation exercise training on pulmonary function and exercise endurance of patients with pneumoconiosis,” *Chinese Journal of Rehabilitation Medicine*, vol. 32, no. 6, pp. 465–467, 2017.

[41] Q. G. Liu, S. Y. Zhao, X. Zheng, L. Zhao, J. H. Li, and Y. J. Tian, “Observation on the effect of multidisciplinary cooperative respiratory rehabilitation in patients with pneumoconiosis,” *Chinese Journal of Industrial Hygiene and Occupational Diseases*, vol. 27, no. 11, pp. 670–672, 2009.

[42] J. Liu, J. Y. Wang, and D. H. Li, “Application of health education with sports training on pulmonary function among pneumoconiosis patients,” *Chinese Journal of Modern Nursing*, vol. 21, no. 11, pp. 1241–1244, 2015.

[43] X. Y. Li, W. Hu, Z. H. Zhang, and B. Shang, “Effect of comprehensive lung rehabilitation on respiratory function in patients with pneumoconiosis,” *Chinese Journal of Rehabilitation Medicine*, vol. 29, no. 2, pp. 123–124, 2014.

[44] F. Li, J. S. Gao, Y. Han, and L. Chen, “Effect evaluation of comprehensive pulmonary rehabilitation on patients with coal workers pneumoconiosis,” *Clinical Medicine*, vol. 35, no. 1, pp. 30–32, 2015.

[45] Y. Jin, M. Yao, W. Li et al., “Pulmonary rehabilitation therapy of pneumoconiosis patients,” *Chinese Journal of Industrial Hygiene and Occupational Diseases*, vol. 32, no. 11, pp. 849–850, 2014.

[46] D. F. Cao, Z. H. Zhang, P. Gao, B. Shang, Y. F. Zhang, and L. Sun, “Observation on curative effect of comprehensive pulmonary rehabilitation therapy on pneumoconiosis,” *Chinese Journal of Industrial Medicine*, vol. 23, no. 4, pp. 271–272, 2010.

[47] M. T. Dale, Z. J. McKeough, P. A. Munoz, P. Corte, P. T. P. Bye, and J. A. Alison, “Exercise training for asbestos-related and other dust-related respiratory diseases: a randomised controlled trial,” *BMC Pulmonary Medicine*, vol. 14, no. 1, 2014.

[48] L. L. Ma, “Effect of pulmonary rehabilitation therapy on pulmonary ventilation function in patients with stable silicosis,” *For all Health*, vol. 8, no. 9, p. 86, 2014.

[49] C. Z. Liu, “Effect of health education combined with respiratory muscle training on quality of life in patients with coal workers’ pneumoconiosis,” *Occupation and Health*, vol. 30, no. 17, pp. 2392–2394, 2014.

[50] A. Q. Dong, K. C. Li, D. Tang, Y. Xie, and H. Y. Cao, “The effect of systematic rehabilitation on QOL of patients with stage II pneumoconiosis,” *Chinese Journal of Rehabilitation Medicine*, vol. 24, no. 10, pp. 927–929, 2009.

[51] S. Y. Xiao, J. Gao, Z. B. Hua et al., “Effect of exercise-based short-term rehabilitation therapy on pulmonary function of coal workers’ pneumoconiosis,” *China Occupational Medicine*, vol. 46, no. 1, pp. 67–70, 2019.
[53] G. Raghu, B. van den Blink, M. J. Hamblin et al., “Effect of recombinant human pentraxin 2 vs placebo on change in forced vital capacity in patients with idiopathic pulmonary fibrosis: a randomized clinical trial,” *JAMA*, vol. 319, no. 22, pp. 2299–2307, 2018.

[54] J. B. A. Welling, J. E. Hartman, N. H. T. ten Hacken, K. Klooster, and D. J. Slebos, “The minimal important difference for the St George’s Respiratory Questionnaire in patients with severe COPD,” *The European Respiratory Journal*, vol. 46, no. 6, pp. 1598–1604, 2015.

[55] P. W. Jones, “St. George’s Respiratory Questionnaire: MCID,” *COPD: Journal of Chronic Obstructive Pulmonary Disease*, vol. 2, no. 1, pp. 75–79, 2009.

[56] X. Huang, H. Chen, R. Long, and S. Li, “Development and validation of the quality of life scale for Chinese coal miners with pneumoconiosis (QOL-CMP): measurement method and empirical study,” *Journal of Cleaner Production*, vol. 232, pp. 1062–1075, 2019.

[57] B. Han, B. Yan, N. Zhao et al., “The influence of the functional capacity on subjective well-being and quality of life of patients with silicosis,” *Aging & Mental Health*, vol. 17, no. 6, pp. 707–713, 2013.